DK1417307T3 - Oligonucleotidsammensætninger og deres anvendelse til at inducere apoptose - Google Patents
Oligonucleotidsammensætninger og deres anvendelse til at inducere apoptoseInfo
- Publication number
- DK1417307T3 DK1417307T3 DK02767738T DK02767738T DK1417307T3 DK 1417307 T3 DK1417307 T3 DK 1417307T3 DK 02767738 T DK02767738 T DK 02767738T DK 02767738 T DK02767738 T DK 02767738T DK 1417307 T3 DK1417307 T3 DK 1417307T3
- Authority
- DK
- Denmark
- Prior art keywords
- bases
- nebularine
- hypoxanthine
- combinations
- uracil
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000006907 apoptotic process Effects 0.000 title 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 abstract 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 abstract 4
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 abstract 2
- MRWXACSTFXYYMV-UHFFFAOYSA-N Nebularine Natural products OC1C(O)C(CO)OC1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-UHFFFAOYSA-N 0.000 abstract 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 abstract 2
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 abstract 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 abstract 2
- 229940035893 uracil Drugs 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 229940113082 thymine Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B99/00—Subject matter not provided for in other groups of this subclass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Theoretical Computer Science (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Plant Pathology (AREA)
- General Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31329001P | 2001-08-17 | 2001-08-17 | |
| PCT/IB2002/003323 WO2003016528A2 (en) | 2001-08-17 | 2002-08-19 | Oligonucleotide compositions and their use to induce apoptosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1417307T3 true DK1417307T3 (da) | 2009-07-13 |
Family
ID=23215136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02767738T DK1417307T3 (da) | 2001-08-17 | 2002-08-19 | Oligonucleotidsammensætninger og deres anvendelse til at inducere apoptose |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US7199228B2 (da) |
| EP (2) | EP1448986B1 (da) |
| JP (2) | JP4469603B2 (da) |
| KR (2) | KR100943567B1 (da) |
| AT (2) | ATE428781T1 (da) |
| AU (2) | AU2002326067B2 (da) |
| CA (2) | CA2457783A1 (da) |
| DE (2) | DE60211206T2 (da) |
| DK (1) | DK1417307T3 (da) |
| ES (1) | ES2325247T3 (da) |
| IL (4) | IL160408A0 (da) |
| MX (2) | MXPA04001315A (da) |
| WO (2) | WO2003016567A2 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030032610A1 (en) * | 1996-06-03 | 2003-02-13 | Gilchrest Barbara A. | Method to inhibit cell growth using oligonucleotides |
| AU2001251115A1 (en) * | 2000-03-31 | 2001-10-15 | Trustees Of Boston University | Use of locally applied dna fragments |
| US7087586B2 (en) * | 2001-04-24 | 2006-08-08 | Bioniche Life Sciences, Inc. | Oligonucleotide compositions and their use to induce differentiation of cells |
| CA2457783A1 (en) * | 2001-08-17 | 2003-02-27 | Bioniche Life Sciences Inc. | Oligonucleotide compositions and their use to induce apoptosis |
| AU2003259735A1 (en) * | 2002-08-08 | 2004-02-25 | Sirna Therapeutics, Inc. | Small-mer compositions and methods of use |
| US20060269924A1 (en) * | 2003-04-11 | 2006-11-30 | Trustees Of Boston University | Modulation of telomere-initiated cell signaling |
| WO2007028985A2 (en) * | 2005-09-07 | 2007-03-15 | The Secretary Of State For Defence | Adjuvanted vaccine |
| GB0906234D0 (en) | 2009-04-14 | 2009-05-20 | Secr Defence | Vaccine |
| KR100998365B1 (ko) | 2009-06-29 | 2010-12-06 | 압타바이오 주식회사 | 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체 |
| EP2498816A4 (en) * | 2009-11-10 | 2013-12-18 | Bioniche Life Sciences Inc | POLYNUCLEOTIDE COMPOSITIONS CONTAINING NON-DNA BASES AND THEIR USE FOR MODULATING IMMUNE RESPONSES |
| US8740314B2 (en) * | 2011-01-11 | 2014-06-03 | Joy Mm Delaware, Inc. | Bit holding system with an opening for removal of broken bits |
| CN106709925A (zh) * | 2016-12-30 | 2017-05-24 | 上海联影医疗科技有限公司 | 医学图像中椎块的定位方法及其装置 |
| CN107704697B (zh) * | 2017-10-18 | 2019-08-20 | 西南交通大学 | 一种型材三维拉弯成形性预测评价优化方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5106727A (en) * | 1989-04-27 | 1992-04-21 | Life Technologies, Inc. | Amplification of nucleic acid sequences using oligonucleotides of random sequences as primers |
| WO1993018187A1 (en) * | 1992-03-13 | 1993-09-16 | California Institute Of Technology | Triple helix recognition of dna |
| US5962426A (en) * | 1993-06-25 | 1999-10-05 | Yale University | Triple-helix forming oligonucleotides for targeted mutagenesis |
| DK0805876T3 (da) * | 1995-01-19 | 2000-11-06 | Gen Probe Inc | Nukleinsyreamplifikationsoligonukleotider og prober til Lyme-sygdom-associeret Borrelia |
| US5643890A (en) | 1995-01-31 | 1997-07-01 | The Board Of Regents Of The University Of Nebraska | Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases |
| CA2365980A1 (en) * | 1999-04-08 | 2000-10-19 | Oasis Biosciences, Inc. | Amplification and sequencing primer pairs and use thereof |
| ATE455851T1 (de) | 1999-12-13 | 2010-02-15 | Bioniche Life Sciences Inc | Therapeutisch nützliche synthetische oligonukleotide |
| WO2003070888A2 (en) * | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid |
| CA2457783A1 (en) | 2001-08-17 | 2003-02-27 | Bioniche Life Sciences Inc. | Oligonucleotide compositions and their use to induce apoptosis |
-
2002
- 2002-08-19 CA CA002457783A patent/CA2457783A1/en not_active Abandoned
- 2002-08-19 AT AT02767738T patent/ATE428781T1/de active
- 2002-08-19 IL IL16040802A patent/IL160408A0/xx unknown
- 2002-08-19 US US10/223,672 patent/US7199228B2/en not_active Expired - Fee Related
- 2002-08-19 WO PCT/IB2002/003324 patent/WO2003016567A2/en not_active Ceased
- 2002-08-19 US US10/223,234 patent/US7200531B2/en not_active Expired - Fee Related
- 2002-08-19 EP EP02760451A patent/EP1448986B1/en not_active Expired - Lifetime
- 2002-08-19 KR KR1020047002322A patent/KR100943567B1/ko not_active Expired - Fee Related
- 2002-08-19 WO PCT/IB2002/003323 patent/WO2003016528A2/en not_active Ceased
- 2002-08-19 DK DK02767738T patent/DK1417307T3/da active
- 2002-08-19 CA CA002457789A patent/CA2457789A1/en not_active Abandoned
- 2002-08-19 JP JP2003521874A patent/JP4469603B2/ja not_active Expired - Fee Related
- 2002-08-19 DE DE60211206T patent/DE60211206T2/de not_active Expired - Lifetime
- 2002-08-19 AT AT02760451T patent/ATE325341T1/de not_active IP Right Cessation
- 2002-08-19 IL IL16040702A patent/IL160407A0/xx unknown
- 2002-08-19 JP JP2003521837A patent/JP4504015B2/ja not_active Expired - Fee Related
- 2002-08-19 AU AU2002326067A patent/AU2002326067B2/en not_active Ceased
- 2002-08-19 EP EP02767738A patent/EP1417307B1/en not_active Expired - Lifetime
- 2002-08-19 DE DE60231986T patent/DE60231986D1/de not_active Expired - Lifetime
- 2002-08-19 AU AU2002330663A patent/AU2002330663B2/en not_active Ceased
- 2002-08-19 ES ES02767738T patent/ES2325247T3/es not_active Expired - Lifetime
- 2002-08-19 MX MXPA04001315A patent/MXPA04001315A/es active IP Right Grant
- 2002-08-19 KR KR1020047002321A patent/KR101017483B1/ko not_active Expired - Fee Related
- 2002-08-19 MX MXPA04001480A patent/MXPA04001480A/es active IP Right Grant
-
2004
- 2004-02-15 IL IL160407A patent/IL160407A/en not_active IP Right Cessation
- 2004-02-15 IL IL160408A patent/IL160408A/en not_active IP Right Cessation
-
2007
- 2007-01-24 US US11/626,614 patent/US7893242B2/en not_active Expired - Fee Related
- 2007-02-09 US US11/705,044 patent/US20080077372A1/en not_active Abandoned
-
2011
- 2011-02-07 US US13/021,983 patent/US8350016B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1417307T3 (da) | Oligonucleotidsammensætninger og deres anvendelse til at inducere apoptose | |
| ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| ATE468336T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| DK1539783T3 (da) | Inhibitorer af nucleosidphosphorylaser og nucleosidaser | |
| ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| IL173888A0 (en) | Novel tricyclic nucleosides or nucleotides as therapeutic agents | |
| DE602004024572D1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
| ES2235353T3 (es) | Naftridonas para inhibir la proteina tirasina quinasa y proliferacion celular mediada por la quinasa del ciclo celular. | |
| ATE320426T1 (de) | Harnstoffderivate und ihre verwendung | |
| DK1663242T3 (da) | 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler | |
| DK1045690T3 (da) | Benzensulfonamidinhibitorer af PDE-IV og deres terapeutiske anvendelse | |
| PA8571001A1 (es) | 2-(2,6-diclorofenil)-diarilimidazoles | |
| MX2007014619A (es) | Pirrolopiridinas de utilidad como inhibidores de proteina quinasa. | |
| DE60024660D1 (de) | Menschliche rnase h und entsprechende oligonukleotidverbindungen | |
| EA200801372A1 (ru) | Способы получения замещенных пиримидинов | |
| PA8550101A1 (es) | Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización | |
| AP2000002016A0 (en) | 2-(Purin-9-yl) Tetrahydrofuran-3,4-diol derivatives. | |
| GT200300294A (es) | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso | |
| DK1325011T3 (da) | Fremgangsmåder og forbindelser til behandling af proliferative sygdomme | |
| ATE292677T1 (de) | Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| DK1339853T3 (da) | Isolerede luciferaser og deres anvendelse | |
| BRPI0415355A (pt) | triarilimidazóis | |
| DE60326348D1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
| DK1537210T3 (da) | Decoy-oligonukleotid-inhibering af CD40-ekspression |